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Fluticasone Propionate Does not Influence Bone 
Metabolism in Contrast to Bedomethasone Dipropionate
GERBEN P. BOOTSMA, P. N. RICHARD DEKHUIJZEN, JAN FESTEN, PAUL C. H. MULDER,
LEON M. J. W. SWINKELS, and CEES L. A. van HERWAARDEN
Department of Pulmonary Diseases and Department of Experimental and Chemical Endocrinology, University Hospital, Nijmegen, 
and Institute of Epidemiology and Biostatistics, Erasmus University, Rotterdam, the Netherlands
Inhaled corticosteroids (ICS) in dosages above 1,000 j^g/d may influence parameters of bone metabo­
lism. Fluticasone propionate (FP) is a new ICS with a higher clinical potency than bedomethasone dipropi­
onate (BDP) combined with negligible oral bioavailability. The aim of this study was to evaluate the 
effects of FP and BDP in clinically equipotent dosages on indices of bone metabolism and morning 
cortisol. FP 750 |ig/d and BDP 1,500 jig/d were compared in a randomized, double-blind, crossover 
study consisting of two 6-wk treatment periods, each preceded by a 3-wk single-blind placebo period. 
Twenty-one nonsmoking asthmatics completed the study. FP had the same effect on FEVi and peak 
expiratory flow as the double dose of BDP. Both treatments did not change morning cortisol. BDP 
decreased both osteocalcin and procollagen type 1 carboxyterminal propeptide, indices of bone for­
mation, significantly by 18.5 and 21.9%, respectively. In contrast, FP did not change any variable of 
bone formation. FP and BDP did not increase type 1 collagen carboxyterminal telopeptide and deoxy- 
pyridinoline crosslinks, both markers of bone resorption. If changes in parameters of bone metabolism 
indicate adverse effects on bone quality in the long term, FP may offer an advantage over BDP. Bootsma 
GP, Dekhuijzen PNR, Festen J, Mulder PGH, Swinkels LMJW, van Herwaarden CLA. Fluticasone 
propionate does not influence bone metabolism in contrast to  bedomethasone dipropionate.
AM J RESPIR CRIT CARE MED 1996;153:924-30.
Inhaled corticosteroids (ICS) are frequently used in the treat­
ment of patients with asthma (1-3). In current guidelines, treat­
ment of patients with severe asthma with dosages as great as 2,000 
|j,g daily is recommended (1,2). These dosages are associated with 
systemic effects such as a decrease in morning cortisol (3) and 
adverse effects on markers of bone metabolism.
Fluticasone propionate (FP) is a new ICS with a higher topi­
cal anti-inflammatory effect in humans than ICS such as beclo- 
methasone dipropionate (BDP) (4). In clinical studies FP is as 
potent as the double dose of BDP with regard to bronchial hyper­
responsiveness, FEVlf peak expiratory flow rate (PEFR), and 
symptom scores (5-7). In addition, FP has negligible oral bioavail­
ability (8). However, as the majority of the systemic available 
dose will reach the bloodstream after absorption from the lungs, 
assessing the overall systemic activity remains necessary. Data 
currently available suggest that in equipotent dosages, FP may 
have less effect on the hypothalamic-pituitary-adrenal (HPA) axis 
than BDP (5, 6).
The other above-mentioned potentially serious side effect of 
ICS concerns bone quality and metabolism. Osteoporosis may
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be the most important side effect of long-term treatment with 
oral corticosteroids (OCS) (9). ICS in dosages ranging from 400 
to 3,200 ng daily may decrease markers of bone formation (10-14) 
and increase indices of bone resorption (10).
The aim of this study was to compare the effects of FP 750 
fig/d and BDP 1,500 |xg/d for 6 wk on markers of bone metabo­
lism and cortisol in adult patients with asthma.
METHODS
Patients
Thirty nonsmoking patients with asthma 18 to 55 yr of age (mean, 30.3 
yr) were recruited from the out-patient department. Their characteris­
tics are summarized in Table 1. All women were premenopausal. No pa­
tient had any other pulmonary disease or serious concomitant disease 
and none reported bone fractures in the preceding 3 yr or had reported 
spontaneous fractures at all. All patients had been receiving regular treat­
ment with BDP or budesonide for an average of 5.4 yr (range, 0.3 to 
16 yr) with an average daily dose of 790 p.g (range, 400 to 1,600 |xg). 
None had used OCS as maintenance treatment, i.e., continuously for 
more than 3 mo, but 13 patients had needed short courses of OCS in 
the past to treat exacerbations. No patient had used OCS in the preced­
ing 6 mo. The study was approved by the Nijmegen University medical 
ethics committee. All study subjects gave written informed consent be­
fore entry into the study.
Protocol
The study was a randomized, crossover trial consisting of a 3-wk single­
blind washout (placebo) period before each of the two 6-wk double­
blind active treatment periods (flow-chart in Figure 1). Treatment ran­
domization was performed prior to the first placebo period, but at the
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TABLE 1
BASELINE CHARACTERISTICS OF THE PATIENTS
At Start of the Study Period (run-in)
Subjects, n 
Sex, M/F 
Age, yr
Duration of asthma, yr 
Allergy, positive 
Baseline FEVj 
% pred 
L
Morning PEFR, L/min 
Evening PEFR, L/min 
Duration of ICS use, yr 
Patients using OCS in the past, n 
Total courses, n
30 
14/16 
30.3 ± 7.4* 
17,6 ± 9.7 
25
21 
10/11 
30,2 ± 8.1* 
17.5 ± 10.0 
18
84,8 ± 18.8 
3.21 ±0.80
5.4 ± 4.0 
13
1.5 ± 3.4
— --V - » . f c  ' • ' A h «  *■> . ' . f r  1 1  «■--< < ■ ■ i  ,  K v i . ' r . ' j  r  . - 4 -*--0 . s - V *  i r , Kw  | -» • '« i
Definition of abbreviations: PEFR =  peak expiratory flow rate; ICS = inhaled cortico 
steroids; OCS = orally administered corticosteroids.
* Values are m ean ±S D .
1,25-dihydroxyvitamin D3 (l,25[OH]2D3) were determined in blood. As 
markers of bone formation, serum alkaline phosphatase (AP), osteocal­
cin (OC), and carboxyterminal propeptide of type 1 procollagen (P1CP) 
After First Placebo were measured (15-17). Markers of bone resorption included carboxy­
terminal cross-linked telopeptide of type 1 collagen (1CTP) and urin­
ary calcium, hydroxyproline (HP), and deoxypyridinoline (Dpd) cross­
links (15, 16).
Ca, P, AP, and creatinine (Cr) were automatically determined on a 
Hitachi 747 automatic analyzer (Boehringer, Mannheim, Germany) ac­
cording to standard hospital procedures. Blood samples for measure­
ments of OC, P1CP, 1CTP, and l,25(OH)2D3 were immediately cen­
trifuged and kept at -20° C until assayed later. OC was measured using 
a commercial OSTK-PR radioimmunoassay (Cis, Gif sur Yvette, France); 
intra-assay coefficient of variation (CV) was 3.0 to 3.6% and interassay 
CV was 5.5 to 6.6% at serum levels of 0.22 to 4.26 nmol/L. P1CP and 
1CTP were measured using a radioimmunoassay kit (Orion Diagnostics, 
Espoo, Finland); for P1CP intra-assay CV was 2.1 to 2.7% and interas­
say CV was 4.1 to 6,6% at levels of 103 to 216 ng/L; for 1CTP intra­
assay CV was 6.2% and interassay CV was 7.9% at levels o f 3.8 and 
3.3 ng/L, respectively. 1,25 (OH)2Dj radio receptorassay was performed 
after diethylether extraction and paper chromatography of the samples. 
Tritriated vitamin D3 was added to 1 to 2 ml of plasma prior to extrac­
tion. Extracts were dried under nitrogen and chromatographed (intra­
assay CV, 10.5%; interassay CV, 11.5% at levels of 93 and 103 pm ol/L , 
respectively) (18). Blood samples for plasma-intact PTH were immedi­
ately placed on ice and determined by means of an immunoradiometric 
assay (Nichols Institute, Wychen, the Netherlands); intra-assay C  V was
74.7 ± 18.1 
2.84 ± 0.77 
405.8 ± 105.9 
440.0 ± 73.1 
5.1 ± 4.0 
7
1.3 ± 3.7
end of this first 3-wk placebo (run-in) period, patients needed to have 
asthma symptoms and a FEV, of > 50% of predicted. Hence, not all 
randomized patients entered the first treatment period because of non­
treatment-related baseline inclusion criteria. Measurements performed 
after the two placebo periods were used as baseline values prior to ac- 1-8 t0 and interassay CV was 3.1 to 6.5% at levels of 2.3 to 4.2 
tive treatment. Patients inhaled 375 ng FP or 750 jxg BDP or placebo nmol/L. Urine for determination of HP and Dpd was frozen at -20° C
by metered-dose inhaler (MDI) twice daily. They used salbutamol 100 
Hg MDI as rescue medication. No other pulmonary medication was al­
lowed. Patients were instructed how to use their MDI correctly.
Before and after each active treatment period (Measurements 1 to 
4 in Figure 1), lung function tests were performed, and blood and urine 
samples were taken. Subjects were not allowed to use rescue and study 
medication for at least 8 h before each visit.
Clinical efficacy. To assess basal lung function, flow-volume curves 
were performed and recorded on a heated pneumotachograph (Spiro 
Analyzer ST-250®; Fukuda Sangyo Co., Tokyo). FEVi was recorded as 
the best of three reproducible values (within 5%). During the last 3 wk 
of the four periods patients recorded their PEFR on a diary card at home.
and processed later. Total HP, determined in the 2-h fasting urine to 
exclude dietary sources on HP excretion (12,15,16), was measured using 
the Hypronosticon kit (Organon Teknica, Boxtel, the Netherlands); CV 
for the determination of HP was 11.8%. Analysis of Dpd was per formed 
by Elisa (Metra Biosystems, Palo Alto, CA); intra-assay CV was 6.0% 
and interassay CV was 10.8% at a urine level of 17.7 nmol/mmol Cr). 
All measurements were performed in duplicate. Values for urinary HP, 
Dpd, and Ca were standardized by the creatinine concentration o f the 
sample and expressed as a ratio per mmol creatinine (HP/Cr, Dpd/Cr, 
and Ca/Cr).
Statistical Analysis
The best of three PEFR measurements on a mini-Wright peak flow me- a  first- and second-order carryover effect can be distinguished, o f which
ter in the morning and evening before medication was recorded. 
Laboratory measurements. On the mornings of Visits 1 to 4, a ve- only the latter may interfere with the treatment effect. Therefore, a p value > 0.01 was taken for the second-order carryover effect to suppos- 
nous blood sample and a urine sample were taken during the first 2 h edly exclude any influence on treatment effects. The first-order carryover 
after initial voiding after a 12-h overnight fast. Blood and urine were effect was tested by comparing the differences of Measurements 3 and
taken between 7:00 and 9:00 a.m. (for individual patients always at the 1 between treatment-order groups. The second-order carryover effect
same time) prior to lung function measurements. To assess effects on was tested by comparing the sum of two differences (i.e., 2 minus 1 and 
adrenal function, morning plasma cortisol was determined using an in- 4 minus 3) between treatment-order groups. In this way a necessary ad- 
house radioimmunoassay involving heat inactivation of corticosteroid- justment was made for the unbalance present in several variables at Mea- 
binding globulin. For the analysis of calcium and phosphate metabo- surement 1 in order to prevent this unbalance from interfering w ith the 
lism, calcium (Ca), phosphate (P), parathyroid hormone (PTH), and carryover
placebo
w ash-out
(run-in)
placebo
w ash-ou t
\ 0 \ #* 4\ 0 S t\ #\ 4 \ #
/ V / */ V
4 \Ì \/ *# \
^  *-----------
FP
BDP
Provided there was no second-order carryover effect, the difference 
in treatment effect between FP and BDP was tested next by comparing 
the di fference of Measurements 2 and 4 between treatment-order groups: 
(the mean difference in effects between FP and BDP can be calculated 
as [(FP-BDP) - (BDP-FP)]/2 (19). The treatment effects of bo th  ICS 
(A-effect) were also expressed by taking the difference between real base­
line values and the corresponding values after treatment. FEV(and PEFR 
data are shown as absolute values. The mean of all values o f PEFR 
recorded during the last 2 wk of each period was used for statistical analy­
sis. Wilcoxon’s signed rank test or the paired t-test were used for analy­
sis when appropriate; p values less than 0.05 were considered signifi­
cant. Results are reported as means ± SEM.
3 weeks 6 weeks 3 weeks 6 weeks RESULTS
Thirty patients entered the first placebo (run-in) period. Seven 
patients dropped out in the run-in period because of an exacer- 
1 2 3 4 bation of their asthma. At the end of this period, two other pa­
tients did not meet the final inclusion criteria because they expe- 
Figure 1. Design of the study. FP = 750 (xg fluticasone propionate rienced no asthma symptoms. The remaining 21 patients all
Measurements
daily; BDP = 1,500 ng beclomethasone dipropionate daily. completed the study. Their characteristics are summarized in Ta-
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TABLE 2
■TREATMENT-EFFECT
TWO
- r  w  » — â - . k - >  —
Differences in Treatment
■ n  1^ «  ' H l  r . . + \ '.V i » V i *  i > v  ► r r — r ' A »  ... ...........................................*
First-Order
Carryover
Effect
Second-Order
Carryover
Effect
Effect FP-BDP
p Value
n--- • --m- .  . .  ■■■ , .----- » — m k  w  , ,
(mean ± SEM) (95% Cl)
Calcium metabolism
Ca p = 0.81 p = 0.41 -0 .04 ± 0.02 -0.09 to 0.003 p = 0.06
P p = 0.63 p = 0.80 0.02 ± 0.04 -0.07 to 0.11 p = 0.61
PTH p *  0.10 p = 0*12 0.11 ± 0.19 -0.28 to 0.51 p = 0.53
1,25(OH)2D3 p = 0.88 p = 0.97 11.8 ± 11.0 -11.3 to 34.9 p = 0.27
Bone formation
AP p = 0.84 p = 079 1.29 ± 1.4 -1.61 to 4.18 p = 0.36
OC p = 0.67 p = 0,99 0.29 ±0.11 0.06 to 0.52 p ^ 0,02
PI CP p = 0.78 p = 0.93 23.7 ± 8.0 6.88 to 40.5 p = 0.008
Bone Resorption
1CTP p -  0.12 p = 0,19 0.04 ± 0.04 -0.05 to 0.12 p = 0.24
U Ca/Cr p = 0.48 p = 0,26 0.02 ± 0.03 -0.05 to 0.10 p « 0.57
U HP/Cr p ~ 0.28 p = 0,07
U Dpd/Cr p = 038 p = 0.48 0.10 ± 0.80 -1.58 to 1.79 p = 1.00
Adrenal function
Cortisol p “ 0*09 p = 035 0.04 ± 0.04 -0.05 to 0.12 p = 0.36
Definition o f abbreviations: FP ~ fluticasone propionate; BDP = beclomethasone di propionate; Ca « calcium; P = phosphate; PTH = 
parathyroid hormone; 1 ,25(OH)2& i ~ 1,25-dìhydroxy-vitamin D3; AP -  alkaline phosphatase; OC ~ osteocalcin; PI CP = carboxyterminal 
propeptide of type 1 procollagen; 1CTP = carboxyterminal cross-linked telopeptide of type 1 collagen; U Ca/Cr = urinary calcium/creati­
nine ratio; U HP/Cr = urinary hydroxyproiine/creatinine ratio; U Dpd/Cr = urinary deoxypyridinoline/creatinine ratio.
* The treatment effects of FP and BDP are directly compared by analyzing the difference oi the treatment effects between treatment- 
order groups E(FP-BDP) -  (BDP-FP)]/2.
ble 1. O f these patients, 14 started with BDP and seven started after BDP (p < 0.01), but not after FP (mean increase, 3.5 ±
5.1%) (Table 3 and Figure 2). The levels of OC and P1CP after
6 wk of treatment with BDP returned to baseline values after
withdrawal of BDP (Table 4). Direct treatment-effect compari-
with FP.
The p values of first- and second-order carryover effects of
Täble 2
line/creatinine ratio showed a second-order carryover effect and son between FP and BDP showed to be significantly different 
was excluded from further analysis. There were no carryover ef~ in effects on OC and P1CP (Table 2).
fects significant at 10% for the other variables studied. No sig­
nificant differences existed between the two baseline values (Mea­
surements 1 and 3).
Clinical Efficacy
Both FP and BDP caused a significant increase in FEV, and 
morning and evening PEFR. With FP the A-effect on FEV, BDP were found (Thble 2).
was 0.45 ± 0.12 L, and with BDP it was 0.34 ± 0.09 L (both
Bone Resorption
1CTP decreased after BDP (-11.5 ± 8.2%; p < 0.05), but not 
after FP(-3.8 ± 3.8%;p = 0.18)(T^ble3). Urinary Ca/Cr and 
Dpd/Cr did not change after treatment. For all variables of bone 
resorption, no differences in treatment effects between FP and
p < 0.01). Compared with baseline, morning PEFR increased by 
51.4 ± 10.4 and 46.4 ± 9.6 L/min, and evening PEFR increased 
by 39.8 ± 8.2 and 29.2 ± 9.4 L/min after FP and BDP, respec­
tively (all p < 0.01). The diurnal variation in PEFR decreased 0.06 |imol/L after BDP (p = 0.68). In none of the patients did 
significantly after FP (A-effect, -10.8 ± 4.3 L/min; p < 0.01),
Adrenal Function
Mean cortisol values changed from 0.64 ± 0.06 to 0.61 ± 0.06 
|amol/L after FP (p = 0.42) and from 0.60 ± 0.06 to 0.59 ±
but not after BDP (A-effect, -10.7 ± 6.0 L/min; p 0.14).
the cortisol level fall below the lower limit of normal in our lab­
oratory (0.19 |imol/L). There were no significant differences in
A direct comparison of the treatment effects showed no signifi- treatment effects between FP and BDP (Table 2). 
cant differences between FP 750 fxg daily and BDP 1,500 jug daily.
Calcium, Phosphate, and Regulating Hormones
Serum Ca, P, PTH, and l,25(OH)2D3 were not significantly 
changed by FP and BDP (Table 3). After both ICS, Ca and P 
changed less than 1 and 3% from baseline, respectively. PTH 
increased by 6,3 ± 6.0% after FP and by 7.1 ± 5.6% after BDP. 
l,25(OH)2D3 increased by 18.6 ± 8.3% after FP and by 11.3 ± 
6.6% after BDP. No significant differences between the treat­
ment effects of FP and BDP were found (Table 2).
Bone Formation
V
AP did not change after FP and BDP (Table 3). OC and P1CP, 
however, were significantly decreased after BDP, but not after 
FP. OC decreased by 18.5 ± 3.9% after BDP (p < 0.001) and by
5.5 ± 3.6% after FP (p = 0.16). P1CP decreased by 21.9 ± 6.8%
DISCUSSION
This crossover study in asthmatic patients shows that BDP 1,500 
M-g daily for 6 wk caused a significant depression of OC and P1CP, 
both markers of bone formation. In contrast, FP did not change 
any variable of bone formation. Both FP and BDP did not af­
fect indices of bone resorption, calcium metabolism, or cortisol. 
With regard to clinical efficacy, FP 750 M-g daily was as effective 
as the double dose of BDP on FEV, and PEFR.
As one of the important side effects of corticosteroids may 
be osteoporosis, we measured in this study effects of FP and BDP 
on biochemical markers of bone metabolism. OC is a very sensi­
tive marker of osteoblast activity, as most serum OC originates 
from new cellular synthesis (17). OC is a specific marker of bone 
formation in processes with uncoupled bone formation and re­
sorption, as is the case in glucocorticoid-induced osteoporosis
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TABLE 3
h w '  f i  I v * * *  V |«11
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A-EFFECTS OF FP AND BDP ON BONE
j  (  w  r  ]--  14 ■ _  1 ,  _____-[ 1  | - | )  ■ r  .  1 ^ 1  4» •  *“  * •  4  V- * 1  1 ■
METABOLISM
1 ..................... - r - ^ .  m  — m  \--v» . . . »  . . ' j ? .  v r ' s t - -  • -  —  • • ' . . v - n - '  iv - .  —  - 1-  » •  ' 1 . . . . .  • - •  • — ■ ---------- ' 1
Reference Baseline After 6 Weeks of Therapy
ariable Value ICS (mean ±  SEM) (mean ±  SEM)
1 1 _ .  m  n  -i t  - i  --------- 1 ■ -------- ■ « » . • - ¿ » ■ - .■ m ii . .  . i - i - v - w i - i  « - - » » -  ' '
p Value*
!aldum metabolism
Calcium, n.mol/L (2.20-2.60) FP 2.32 ± 0.02 2.29 ± 0.02 NS
BDP 2.32 ±0.02 2.33 ±0.02 NS
Phosphate, nmol/L (0.80-1.30) FP 1.04 ± 0.04 1.07 ± 0.04 NS
BDP 1.08 ± 0.04 1.06 ± 0.04 NS
PTH, nmol/L (F 0.93-4.97) FP 2.95 ±0.16 3.09 ±0.22 NS
(M 1.25-4.89) BDP 2.70 ±0.16 2.85 ±0.23 NS
1,25(OH)2D î , pmol/L (80-200) FP 129.9 ± 7.5 149.0 ± 11.4 NS
BDP 128.4 ± 10.5 132.5 ±7 .9 NS
one formation
AP, U/L «  120) FP 49.4 ± 3.1 4 7.6 ± 2 .6 NS
BDP 49.9 ± 3.3 47.1 ± 2.7 NS
OC, nmol/L (F 0.47-1.95) FP 1.86 ±0.10 1.74 ±0.11 NS
(M 0.68-2.44) BDP 1.82 ±0.12 1.49 ±0.58 0.000
PI CP, ng/L (F 14-231) FP 140.4 ±10.4 141.2 ±  10.1 NS
(M 38-202) BDP 139.2 ± 8.8 117.3 ±9 .6 0.004
one resorption
1CTP, ng/L (1.37-5.65) FP 3.51 ±0.26 3.33 ±0.26 NS
BDP 3.48 ± 0.26 2.95 ±0.25 0.03
U Ca/Cr, mmol/mmol «  0.45) FP 0.21 ± 0.03 0.20 ± 0.02 NS
BDP 0.23 ± 0.04 0.18 ±0.03 NS
U Dpd/Cr, nmol/mmol (F 2.5-6.0) FP 5.05 ± 0.50 5.19 ±0.54 NS
(M  2.5-5.0) BDP 5.84 ± 0.79 5.32 ± 0.60 NS
. r . ' . « " . N  y  ..-■  '  S - - « i  • r  < ■ ■ ■- : ■ •  • -  . . ' < • ■« ■
Definition of abbreviations: F = female; M = male. For other definitions, see Tables 1 and 2.
* Values of A-treatment effects are calculated as values after 6 wk of treatment versus corresponding baseline values,
(15). P1CP specifically measures collagen type 1 synthesis, the reflected in the concentration of crosslinks, and Dpd is more spe-
major collagen product produced by osteoblasts. It is cleaved cific for osseous tissue than are pyridinoline crosslinks (16). As
from collagen type 1 during its processing to fibrils (one liber- 1CTP does not change to the same extent as P1CP in situations
ated propeptide for every formed collagen molecule: 1:1). It re- in which the metabolic rate of trabecular bone is affected, as is
fleets the changes in whole bone tissue. P1CP decreases in thera- the case with glucocorticoids, a net formation of type 1 collagen
pies that slow the metabolic rate of bone as glucocorticoids (15, (P1CP/1CTP) cannot be calculated.
16). Markers of bone resorption included 1CTP and Dpd cross- Biochemical markers do, however, possess some
links (15, 16). 1CTP measures the degradation of mature type falls. Osteocalcin is regulated at the gene level by 1,25-vitamin D;
I collagen (containing pyridinoline crosslinks). 1CTP increases therefore, osteocalcin may be elevated in patients with abnor-
in diseases that degrade the surface (cortical part) of bone tissue mal serum 1,25-vitamin D levels. Osteocalcin is cleared by the
(e.g., rheumatoid arthritis, bone metastasis), but it changes only kidneys, so patients with renal failure can exhibit increased lev-
a little when trabecular bone is affected as is the case with gluco- els of osteocalcin without a concomitant increase in bone for-
corticoid therapy (15). Changes in trabecular bone are better mation. Moreover, osteocalcin exhibits a marked diurnal varia-
A 2.25 -,
2.00
Osteocalcin
nmol. 1 1.75
1.50
o
#*■»
Baseline 6 baseline 6
weeks
BDP
weeks
FP
B 175
150
PICP
M9-I
-1 125
100
0
Baseline 6
weeks
BDP
i f l w m  
.  w *
baseline 6
weeks
FP
Figure 2. Mean ± SEM baseline values and corresponding values of (A) osteocalcin and (6) procollagen type 1 carboxyterminal propeptide 
(PICP) after 6 wk of treatment with 1,500 ng BDP daily (open bars) and 750 |4,g FP daily (hatched bars). NS = not significant; *p < 0.05; 
**p < 0.01; ***p < 0.001.
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tion, and the serum antigen loses its immunologic activity at room No increase in parameters of bone resorption were found in
temperature or by repeatedly freezing and thawing (15,16). P1CP the present study. This is in line with the findings in most studies
also exhibits diurnal variation (15, 16). Dpd is now considered 
the best available method for bone resorption, although the con­
centration of crosslinks is not invariant in bone, which could 
influence urinary concentration. In addition, Dpd has a marked
on ICS (9, 12, 13, 26, 27). Only Ali and coworkers (10) showed 
an increase in Ca/Cr and HP/Cr ratios after treatment with 2,000 
|ig BDP/d. The statistical analysis in their open study in eight 
healthy subjects, however, raises questions about its interpreta-
diurnal variation (16). In the present study, all samples were im- tion. In the present study, 1CTP decreased after treatment with
mediately determined or frozen and processed at once to exclude BDP (-11.5%, p < 0.05). No differences in direct treatment com-
any influence of laboratory handling. Urinary samples were taken parison between FP and BDP were present. Sorva and cowork- 
after an overnight fast to correct for dietary sources of hydroxy- ers (28) also showed in 14 children a decrease in 1CTP after 1 mo 
proline and corrected for creatinine. Finally, to correct for diur- of treatment with budesonide 800 fig/mVd. Deoxypyridinoline
nal variation, samples were always taken at the same moment 
in individual subjects.
crosslinks in urine, however, did not change. These results are 
in line with the data from a recent cross-sectional study, show-
Osteoporosis may affect as much as 40% of patients receiv- ing no differences in (deoxy)pyridinoline crosslinks between asth- 
ing maintenance treatment with OCS (20). OCS inhibit the in- matic patients without ICS and patients treated with ICS and 
testinal absorption of Ca and P, and they may increase urinary occasionally OCS (27). Altogether, these findings indicate that
in general ICS do not increase bone resorption.
Changes in Ca, P, PTH, or l,25(OH)2D3 did not occur. Previ­
ous short-term studies with ICS did not show adverse effects on 
crease in AP, OC, and P1CP) (13, 21-23) and possibly also in- Ca or P in adults either, even with doses of 2.4 and 3.2 mg/d
(9, 12).
Ca excretion. The resulting decrease in serum Ca evokes second­
ary hyperparathyroidism, reflected in increased serum PTH (21). 
Furthermore, OCS decrease bone formation (reflected in a de-
crease bone resorption (reflected in an increase in Ca/Cr and 
HP/Cr) (21, 23). These changes lead to secondary osteoporosis 
and a rise in (nontraumatic) fracture incidence (20,21,24). OCS 
in doses of 7.5 mg/d or more cause significant loss of trabecular dependent decrease in morning cortisol levels has been reported,
Morning cortisol, used as a marker of adrenal suppression, 
did not change. From dosages of 1,000 \ig/d ICS on, a dose-
bone in most patients, but lower doses of OCS may also have 
adverse effects (25). Furthermore, data suggest that bone loss 
is most pronounced in the early weeks of OCS therapy, with sub­
sequent slowing during prolonged treatment (25).
ICS interact with the same glucocorticoid receptors, and they 
would therefore be expected to act in a similar way after systemic
but at daily doses of approximately 1,500 txg (as in the present 
study), the majority of studies, as recently reviewed by Barnes 
and Pedersen (3), still did not show significant changes. Most 
studies (including ours) did, however, measure only morning se­
rum cortisol, an insensitive method of detecting changes in HPA- 
axis. The study by Nicolaizik and coworkers (29) showed that
absorption. Several short-term studies with ICS, both in healthy at 8:00 a .m . cortisol did not change with ICS, but 24-h urinary
subjects and in patients, have shown a decrease in OC levels af­
ter treatment, indicating effects of ICS on bone formation (11-14,
cortisol levels were significantly depressed. Furthermore, our 
study lasted for only 6 wk, and patients inhaled ICS without a
26). Pouw and coworkers (11) showed that 2,000 |j,g BDP daily spacer. This also may have resulted in our inability to detect any
in healthy volunteers decreased OC by 30% after 8 d of treat­
ment and by 21% after 2 wk of treatment. The present study 
confirms the effect of BDP on parameters of bone formation. 
Both OC and P1CP decreased significantly by 19 and 22%, respec-
changes. Nevertheless, two large studies, both with more than 
150 patients, did report significant differences between FP and 
BDP on HPA-axis, showing an increase in cortisol after 200 and 
1,000 ng FP daily for 4 and 6 wk, respectively, in contrast to a
tively, from baseline after 1,500 M-g BDP daily for 6 wk, suggest- (nonsignificant) decrease after 400 and 2,000 |xg BDP (5, 6).
ing an ongoing depressing effect on bone formation. OC and 
P1CP returned to baseline values after 3 wk of withdrawal (Ta­
ble 4), which suggests that effects on these indices of bone for­
mation are directly related to the treatment with BDP. In con-
Changes in adrenal function are not necessarily related to 
changes in indices of bone formation. Changes in bone metabo­
lism can be detected from 400 |xg BDP daily on (14), in contrast 
to an absence of significant changes in cortisol levels at doses
trast, a clinically equipotent dose of FP did not change these below 800 to 1,000 M-g BDP daily (3). Kiviranta and Tlirpeinen
parameters of bone formation in the same patients. Finally, as 
in most studies (12, 13, 26, 27), both ICS showed no effects on 
AP levels.
TABLE 4
CHANGES IN TIME FOR OSTEOCALCIN AND PI CP IN THE
TWO TREATMENT-ORDER GROUPS*
- --- .> 1  « » r . . M j w t e ü l A -  •  I . ,  I . f  * *  . - - « r y  » .  A h
Measurement (ordered in time)
1 2 3 4
» — I L . m m *  w . , . j
Start BDPt, cross over to FP, n = 14
Placebo BDP Placebo FP
OC, nmol/L 1.96 ±0.13 1.65 ± 0,15 1.99 ± 0.11 1.83 ±0.15
P1CP, ng/L 144.9 ± 11.8 124,7 ±12.9 150.4 ±14.6 149.3 ± 14.2
Start FPÌ, cross over to BDP, n = 7
Placebo FP Placebo BDP
OC, nmol/L 1.60 ±0.12 1.58 ±0.13 1.54 ± 0.20 1.17 ± 0.17
P1CP, ng/L 120.4 ±7.0 125 ±8.5 125.7 ±8.8 102.2 ± 7.0
.  . . . »  < . | . l  " i n . n  1 )  »  i t  . 1  • - « .
For definition of abbreviations, see Tables 1 and 2.
* Values are mean ± SEM. 
t* 1,500 ng daily.
$ 750 ng daily.
(30) also reported effects on carbohydrate metabolism without 
any significant effect on the HPA-axis after treatment with 2,000 
(j,g BDP daily for 5 mo. Apparently, the organs involved may 
have a different sensitivity for ICS.
The present investigation was performed using a crossover de­
sign, which has the potential disadvantage of a carryover effect. 
A carryover effect is statistically detectable only with low power. 
Therefore, a p > 0.1 was taken for the second-order carryover 
effect to exclude any influence on treatment effects. Furthermore, 
after the second washout period (Measurement 3), all but uri­
nary hydroxyproline/creatinine ratio returned to pretreatment lev­
els (Measurement 1) (see Tkble 4). Therefore, carryover effects 
are not likely to have affected the outcome in the present study 
both from a statistical point of view and in terms of clinical rele­
vance.
Another point of discussion is that our patients did not use 
a spacer device to inhale their ICS. The use of a spacer may in­
crease lung deposition, and the fraction deposited in the intrapul- 
monary airways is likely to be absorbed in active form into the 
systemic circulation (3). There is no evidence for local metabo­
lism of FP in the lung. Therefore, the majority will reach the 
bloodstream after absorption from the lungs. It is possible that
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the use of a spacer could have given different systemic effects. 
Nevertheless, the present study compared directly two types of 
ICS, using the same method of administration, making direct 
comparison possible. All patients were fully skilled in using a 
MDI device, and their technique was checked at every visit. All 
patients improved clinically to a great extent. The use of a spacer 
is not likely to have changed the observed differences between 
the two drugs.
Finally, the relevance of effects of ICS on bone metabolism 
are debatable. Kerstjens and colleagues (26) reported that long­
term treatment with ICS did not affect biochemical markers of 
bone metabolism. P1CP and 1CTP remained unchanged after
2.5 yr of treatment with 800 fig BDP daily. Long-term studies 
with higher dosages of ICS have not been reported to our knowl­
edge. The clinical diagnosis of osteoporosis requires the pres­
ence of at least one relatively atraumatic fracture (31). Until now 
no rise in fracture incidence has been reported in patients receiv­
ing long-term ICS treatment. The risk of fracture may be assessed 
by in vivo measurements of bone density. In a prospective study 
for 1 yr in 63 women who had undergone bilateral oophorec­
tomy, there were high correlations between biochemical markers 
(bone-specific AP and urinary HP) and the change in cortical 
area per year (32). Furthermore, in a cross-sectional study of 214 
women who had undergone bilateral oophorectomy up to 12 yr 
previously, changes in bone balance as estimated by differences 
in biochemical markers of bone formation (bone-specific AP) 
and bone resorption (urinary HP) paralleled up to 12 yr, the mea­
sured changes in bone density (31), confirming the validity of 
biochemical markers of bone metabolism.
Decreases in bone density have been suggested after treatment 
with ICS (27, 33). Packe and coworkers (27), measuring density 
of the lumbar spine by quantitative single energy computed 
tomography, showed a mean bone density of 160.4 mg/ml in a 
group of asthmatics treated without ICS compared with 127.5 
mg/ml in a matched group treated with > 1,000 ng BDP and 
courses of OCS for at least 1 yr. In a group of patients treated 
with ICS for at least 3 mo, Ip and colleagues (33) showed with 
dual energy X-ray absorptiometry that bone mineral density was 
decreased at the hip and the lumbar area of the spine in compar­
ison with a matched group of healthy subjects. In these studies 
it is impossible to quantify the contribution of previous OCS 
treatment to loss of bone density. This, however, may be the most 
important factor influencing bone density among other factors 
such as increased age, inactivity, smoking, malnutrition, meno­
pausal status, and genetic predisposition. In order to avoid these 
potential sources of bias with respect to biochemical markers 
of bone turnover, the present study was performed in a crossover 
design in, besides their asthma, healthy premenopausal nonsmok­
ing subjects.
With regard to the higher dosages, advocated by the guide­
lines on the management of asthma (1, 2), it cannot be excluded 
that they have adverse effects on bone in the long term. In this 
respect, the lack of short-term effects on bone metabolism by 
FP 750 |ig/d, in contrast to a clinically equipotent dose of BDP 
1,500 fxg/d, may be of potential interest in the long term.
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